On 30th January 2020 Exscientia announced the first molecule designed by Artificial Intelligence (AI) to enter a Phase 1 Clinical trial. 

The compound, DSP-1181 is being progressed by collaborator Sumitomo Dainippon Pharma as a long-acting and potent serotonin 5-HT1A receptor agonist, with its phase I clinical study to treat obsessive-compulsive disorder as an indication candidate. The project required less than 12 months to complete the exploratory research phase, just a fraction of the time typically required to discover a new candidate molecule.